Btg Share Discussion Threads

[muffmitz] 03/8/2016 10:14

Well, fwiw I'm in again at 6.37. Feels to me like a great buying opportunity supplied by our friends in shiny suits. I'm not talking day trading but to hold for about 3 months at least.

I can flip burgers if I'm wrong....

[steeplejack] 03/8/2016 08:50

The share performance plan is very generous.

[fhmktg] 02/8/2016 08:20

Bob yes!Beads rns

[semper vigilans] 02/8/2016 07:51

Thanks Spyder.

[spyder] 02/8/2016 07:47

LONDON, August 2, 2016 /PRNewswire/ --

BTG plc (LSE: BTG), a global specialist healthcare company, today announced that it has obtained European Conformity (CE) Mark from the Notified Body British Standards Institution (BSI) following completion of the reclassification of DC Bead® and DC BeadM1TM as Class III medical devices under Rule 8 of Annex IX to Directive 93/42/EEC.

The assessment takes account of the characteristics of DC Bead® and DC BeadM1TM with regards to their ability to administer medicines and the product-specific non-clinical and clinical data supporting the safe and effective conditions for use of DC Bead® in the approved clinical setting.

[jadeticl3] 02/8/2016 07:45

bargain bob, you are not alone.

[bargainbob] 02/8/2016 07:29

Fhmktg

Have I missed something ?

[fhmktg] 02/8/2016 07:20

Very good credibility for DC beads AND for the overall reputation of BTG!

[muffmitz] 19/7/2016 17:01

I happened to be looking today at a spreadsheet from 1999. Shares in BTG and ARM were the first I ever seriously bought (apart from those in companies that I was running). I still have them and they both have given me rich rewards, but only after indulging in some serious surf-riding!!

Surfing happens to be one of my hobbies, but not for much longer.....

[bargainbob] 18/7/2016 12:17

Arm holdings takeover , slide in pound to Yen given as main reason .

Something that must impact here, if indeed we think our developments are as good as we think.

[fhmktg] 15/7/2016 10:58

It frays the nerves though!All traders making hay?

[superbarnet] 15/7/2016 09:31

Predictable recovery has started now

[bargainbob] 15/7/2016 07:49

The real growth here is 3 to 5 years away we all know that . A few more bolt ons will happen .
Not sure they can spin Varethena non growth Story much further. Next update there has to be show real traction.

The surprise as usual is why no bid interest in BTG , is it the model is hard to integrate.

[spyder] 15/7/2016 07:01

Yes, thanks Greg, it is good to get some feedback from the 'horse's mouth'!
There is a small mention in the Times that notes that Stifel downgraded BTG to a "hold" after the recent share price run and "little if any signs of an uptick in Varethena sales". Although I also note that the piece makes reference to BTG having posted "first quarter trading numbers" which of course is nonesense!

[steeplejack] 14/7/2016 17:18

Excellent,well balanced and useful comment as ever Greg.

[gregmorg] 14/7/2016 17:11

I went to the AGM and did speak with various executive people before and afterwards. I had read the AGM statement before actually attending so I was forewarned. On reading the statement I did think a spot of share price easing back was likely although these things often go too far. I suspect that is the case here too.

Management gave a good upbeat medium long term presentation at the AGM before the official business(maybe the presentation is already available on the Company's website!) and was talking of having finally positioned themselves for a period of good growth momentum. Prospects for the intervention business did appear to be enhanced as a result of market trends and as a consequence of the recent bolt on businesses. The currency impact, of having hedging against the dollar, was referred to and a range of revenue probabilities shown. Actually I did think they dwelled a bit too much on this aspect but that's a personal view..

We were looking for further guidance on Varithena but not too much was forthcoming . Louise Makin said they had been caught a bit on that one last year so were being particularly cautious in giving guidance. I did not get the impression they were any less optimistic for the product in the medium term and they were still of the view that the momentum would start to step up at some stage during this financial year. The allocation of insurer's code is obviously the key and whilst progress is being made with insurers and physicians, no one wants to be more specific. Could the step up in the vein business timescale be a bit longer than management had expected even a year ago --possibly! Yet the belief in significant revenues from Varithena remains as strong as ever.

So for the short term boys I can understand today's disappointment but this is a long term growth story and it is one we long term shareholders have dealt with for a while. Today's panic looks to me to be completely out of proportion.

As for the recent share sales. I agree they do not look good but often with executive share schemes the executive has no control over the crystallization of the award which also triggers the tax and NI liability. I have seen this time and time again so I am not throwing stones this time. Yet the granting of substantial share options every year establishing a continuous executive enrichment scheme beyond generous executive pay packages does stick in the gullet. The number of pages in the Annual Report devoted to Directors remuneration compared with the number of pages devoted to operational activities does appear out of all proportion. Possibly it tells one that the balance here is not quite right!

[superbarnet] 14/7/2016 15:43

Seen this many times and this represents a big buying opportunity once the shorters stop having fun. It will soon reverse mark my words.

[spyder] 14/7/2016 14:43

I'm still of the opinion that this was a mini-profit warning.
I agree that the currency hedge should have been anticipated, and I don't think the fall simply relates to that news.
The profit warning bit I think comes from the comment about a dip in PneumRx coil sales, and the very bland comment about hoping to see 'reordering' and 'sales growth' with Varithena at sometime during the next 9 months - given near zero reordering and approx ONLY £1m sales of the product to date vs the expected $250m per annum, a couple of reorders and an increase in sales to £2m will be 100% sales growth but of zero value to us.
I find the lack of transparency and commitment regarding Varithena frustrating and worrying, so too does the market, hence the 11% fall on a "non-profit warning". Anything short of a "Varithena sales soar" comment will bee seen as and amount to a profit warning.

[steeplejack] 14/7/2016 14:11

Anyone long of pharmaceuticals and sizeable $ earners in general has had a marvellous run since Brexit .Most welcome to those with heavyweight defensive stocks.

No,not a profit warning as such but analysts would have spoken to the company and put more 'flesh on the bones" post an insipid statement and clearly things are pretty uninspiring as evidenced by a 10% fall in the share price..As for Varientha,the jury remains out but in the absence of a "Varientha is meeting expectations",the market will continue to be underwhelmed.As for the share sales,let's just say that the sales were very canny.

[rrb] 14/7/2016 13:36

BTG use ccy forwards, always have. Investors should have worked out the net impact of weaker GBP is not massive for BTG. So directors not trading on 'insider' information.

[steeplejack] 14/7/2016 13:24

I'm astonished they were given clearance.

In each case the individuals requested consent to deal which was granted by the Chairman in compliance with the Company's share dealing code. The sales took place on 7 July, 2016 on the main market of London Stock Exchange plc. The ISIN of the Ordinary Shares is GB0001001592